Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genflow Biosciences Plc ( (GB:GENF) ) has issued an announcement.
Genflow Biosciences has reported that its total issued share capital as of 31 March 2026 stands at 535,653,205 ordinary shares, all carrying voting rights and with none held in treasury. This updated figure sets the official denominator for investors assessing whether they must disclose new or altered holdings under UK financial transparency rules, clarifying the company’s capital structure for market participants.
The disclosure helps ensure compliance with the Financial Conduct Authority’s guidance by providing a clear baseline for calculating significant shareholdings. For shareholders and prospective investors, the announcement offers greater visibility into Genflow’s equity base at a time when it is progressing gene therapy programs for aging and metabolic disease, potentially influencing governance oversight and institutional interest.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Spark’s Take on GENF Stock
According to Spark, TipRanks’ AI Analyst, GENF is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.
To see Spark’s full report on GENF stock, click here.
More about Genflow Biosciences Plc
Genflow Biosciences Plc is a UK-headquartered biotechnology company with R&D operations in Belgium, focused on pioneering gene therapies for age-related diseases. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is being evaluated in a 12-month proof-of-concept trial in aged dogs, alongside development plans targeting MASH, a prevalent chronic liver disease lacking effective treatments.
Average Trading Volume: 2,284,465
Technical Sentiment Signal: Hold
Current Market Cap: £9.37M
See more insights into GENF stock on TipRanks’ Stock Analysis page.